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Abstract
Background: To assess the efficacy of progressive resistance training (PRT) in increasing strength
and lean body mass (LBM) in HIV‐infected adults.
Methods: Twenty‐five adults with HIV infection were trained using a highly intensive PRT regimen
for 8 weeks, followed by an additional 8 weeks of observation under ad libitum physical activity
conditions.
Results: Twenty‐four of the 25 patients completed the first phase of the study. They had significant
increases in strength on all four exercises tested (P < 0.0001), and an increase in LBM of 1.75 ± 1.94
kg (mean ± SD, P < 0.0002), with a concomitant decline in fat of 0.92 ± 2.22 kg (P < 0.05), and no
significant change in weight or bone mineral content. Twenty‐one of the patients returned for
follow‐up 8 weeks after completing the PRT. Compared with their baseline values, their mean lean
mass remained 1.40 ± 1.8 kg higher (P < 0.003). Among those who continued to train to some
extent, lean mass increased by a mean of 1.1 ± 1.6 kg (n = 9, P < 0.05 versus end of PRT), whereas
those who did no further training showed an increase in lean mass of 0.28 ± 1.4 kg (n = 12, P = NS
versus end of PRT). The difference between the two groups was not, however, significant (P = 0.25).
Among six patients with AIDS wasting, the increase in LBM was larger than among non‐wasted
patients (2.8 versus 1.4 kg, P < 0.06), and there was an increase in both weight (+3.9 versus –0.2 kg,
P < 0.002) and fat mass (+ 0.95 versus –1.5 kg, P < 0.002) at 8 weeks, which persisted at 16 weeks
(weight: +4.0 versus –1.6 kg, P < 0.0002; fat: +1.6 versus –1.9 kg, P < 0.01).
Conclusion: This preliminary study suggests that short‐term, high intensity PRT can significantly
increase LBM and strength in HIV infection, and may be used as an alternative or adjunct to
pharmacological anabolic treatments in this disease.

Introduction
Unintentional loss of weight in patients with HIV infection, or AIDS wasting, is a common
complication of advanced disease, and causes weakness, disability, and death [1–6]. The most
important effect of wasting is the loss of lean body mass (LBM), and especially of muscle mass,
because muscle mass is a major determinant of strength and thus of functional capacity and
disability [7]. Even in the absence of weight loss, lean mass and muscle mass can still be reduced,
because there may be an increase in another component of body composition, such as extracellular
water or fat. We have previously suggested that the term cachexia be reserved for this situation, in
contrast to wasting [8]. Cachexia has similar effects on function and strength to those seen in
wasting, although often to a milder degree.
Even with the advent of highly active antiretroviral therapy (HAART) for HIV infection, data from
longitudinal studies at our center and elsewhere [9,10] suggest that although weight gain occurs
with HAART, a high proportion of this gain is in the fat compartment. Several anabolic treatments
have been shown to increase LBM in HIV infection, including growth hormone, androgen therapy,
and to a lesser extent megestrol acetate [11–14]. Growth hormone is very expensive, however, and
may cause carpal tunnel syndrome, whereas androgens are associated with side‐effects such as
liver disorders, masculinization in women, and testicular atrophy, and perhaps an increased risk of
prostate cancer in men [15,16].
The only physiological intervention known to increase lean mass, muscle mass and strength is
progressive resistance training (PRT). PRT has been shown to be effective in a variety of situations,
including normal ageing, age‐related frailty, and arthritis [17–19]. In each case, the requirement for
a successful increase in lean mass has been the use of a highly intensive regimen (75–80% of the
one‐repetition maximum (1‐RM), the most weight a person can lift in good form). In addition, the
regimen must be progressive: as people become stronger the 1‐RM must be remeasured and the
work load increased to maintain the high intensity. Although anecdotal reports suggest that many
patients with HIV infection do strength train, there has, however, been no systematic study of
highly intensive PRT to increase lean mass in HIV‐infected adults. We now report on the results of
an 8 week, highly intensive PRT intervention followed by 8 weeks of self‐selected physical activity
in patients with HIV infection, with or without AIDS wasting.

Methods
Patient population
Participants were recruited from the Tufts Nutrition for Life cohort, an ongoing study of over 575
men and women with HIV infection, who are being followed at 6 month intervals for an assessment
of the effect of nutritional status on HIV disease progression. Inclusion criteria for the present study
were interest in the study and the ability to give informed consent. AIDS wasting was not required
for entry into the study, but six of the subjects met the criteria for wasting, defined as body mass
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index (BMI) of less than 20 kg/m or an unintentional weight loss of 10% or more of their usual
weight over the previous year [2]. Exclusion criteria included participation in resistance training
over the 6 months preceding study entry, a contraindication to progressive resistance exercise

(myocardial infarction within 6 months, unstable angina, uncontrolled congestive heart failure or
uncontrolled hypertension), diabetes mellitus (an exclusion from the main cohort), renal
insufficiency (serum creatinine > 2.0 mg/dl), hepatic disease (aspartate aminotransferase (AST) or
alanine aminotransferase (ALT) over five times the upper limit of normal, total bilirubin > 2.0
mg/dl), muscle disease (creatine kinase > 500 IU/ml), and arthritis or low back pain, limiting the
activities of daily living. Because PRT has been shown to be useful in some or all of these conditions,
we excluded them in order to study patients with HIV infection alone. Patients taking anabolic
therapy (growth hormone, androgens, or megestrol acetate) were also excluded.

Body composition and nutritional assessment
Subjects were evaluated in the General Clinical Research Center (GCRC) at New England Medical
Center. The usual dietary intake was available on all subjects from their participation in the Tufts
Nutrition for Life cohort, based on food records kept on three non‐consecutive days when the
subjects were consuming a self‐selected diet at home. The food records were collected at baseline,
week 8, and week 16 of the study. A research registered dietitian taught the participants how to
keep a 3 day food record using a food scale (Sunbeam Corporation, Mississauga, Ontario, Canada)
and ruler. Food records were reviewed by the dietitian with the participant at each evaluation. The
food records were evaluated using the Minnesota Nutrient Database, version 2.91. Details of the
dietary intake of the main Nutrition for Life cohort have been submitted for publication elsewhere
(Woods MN, Knox T, Spiegelman D, et al., unpublished observations).
LBM (fat‐free, mineral‐free mass), bone mineral content, and fat mass were estimated by dual
energy X‐ray absorptiometry (DXA) of the whole body using a Hologic QDR 2000 instrument
operating in the array mode. We have previously demonstrated that this method gives estimates of
fat and fat‐free mass that are very close to those obtained with in‐vivo neutron activation analysis,
with a correlation of r = 0.87 and a mean difference of less than 0.5 kg [20]. The coefficient of
variation for five healthy persons measured twice over 2 days was 0.4% of total LBM and 1.4% for
fat mass [21].

Progressive resistance training protocol and strength assessment
Each participant trained three times per week for 8 weeks using Keiser pneumatic resistance
equipment (Keiser Sports Health Equipment Inc., Fresno, CA, USA). The double leg press, leg
(quadriceps) extension, seated chest press, and seated row machines were used in order to focus on
large muscle groups, which have an effect both on whole‐body composition and on function. One
subject had moderate chronic low back pain and did not perform the leg press or quadriceps
extension exercises in most of his sessions. Baseline strength was assessed using the one‐repetition
maximum (1‐RM) test, a measure of the most weight an individual can lift once with good form. The
1‐RM was determined for each of the four exercise machines twice at baseline, and repeated every
2 weeks. Participants trained at 50% of their 1‐RM for the first session, 60% for the second session,
and at 75‐80% of their 1‐RM for the remainder of the sessions. They performed three sets of eight
repetitions on each machine, working with an exercise physiologist on a one‐to‐one basis or in
small groups (two to three volunteers at a time). They were asked to rate the difficulty of each
exercise at the end of each set using a Borg Relative Perceived Effort (RPE) Scale [22], and if the
RPE was less than 16 out of a possible 20, the resistance was increased by 12 lbs without waiting

for the next scheduled 1‐RM test. After each 1‐RM test, the level of resistance was reset to 80% of
the new (and higher) 1‐RM, so that the training remained intensive and progressive during the
entire 8 week program. We have previously used this approach successfully in our laboratory in
frail elderly individuals and patients with rheumatoid arthritis, and observed large increases in
strength without injury or dropout [18,19].

Selfselected activity phase
After the initial 8 week period, subjects were again evaluated in the GCRC as described above. Upon
completing this evaluation, they were asked to return to their usual activity pattern. We did not
think it ethical to discourage subjects who wished to continue to exercise from doing so, therefore
we did not discourage this but asked all subjects to keep logs of their activity. The goal of this phase
was to examine the change in strength and body composition during a period of time without
investigator‐initiated intervention. Therefore, during this phase subjects were not trained at our
center, nor were they in contact with their trainers from the first phase. On the basis of self‐report,
nine of the participants continued to train at least once per week during the next 8 weeks, whereas
12 did no formal training. At the end of 8 weeks, they were again invited to the GCRC for evaluation.

Statistical analysis
All data were examined for normality graphically and statistically. The primary outcome of the
study was the change in LBM assessed by DXA at 8 weeks and at 16 weeks after entry into the
study. Secondary outcomes were changes in strength on each exercise during those periods. These
were compared using analyses of variance (ANOVA). In addition, the differences in the primary and
secondary outcomes by sex, race, medication use, wasting status, and continuation of training
during the second 8 week study period were compared with baseline and week 8 using ANOVA. The
relationship between change in lean mass or strength and dietary energy and protein intake was
examined using linear regression. Differences between the groups were considered to be
statistically significant if the two‐tailed P‐value was less than 0.05.

Results
Study population
The study participants were 20 men and five women, with a mean age of 39 (range 25–56 years)
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and a mean BMI of 24.2 kg/m (see Table 1). The study group included 11 African Americans and 14
whites. Nine of the volunteers had contracted HIV through intravenous drug use, 15 through
homosexual contact, and one through a blood transfusion. The study was carried out between
January, 1995 and May, 1998. Seven of the participants (28%) were homeless or living in shelters.
Six of the patients had AIDS wasting, defined as a loss of more than 10% of their usual body weight
2
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over the previous year or a BMI (kg/m ) below 20 kg/m [2]. At the start of the study no subjects
were participating in regular exercise, defined as 30 min or more of exercise that leads to
perspiration at least three times a week, but three subjects had had experience with weight‐lifting
in the past. None of these three had been training in the previous 6 months. Mean (± SD) dietary

energy intake was 2592 ± 723 kcal/day, and did not differ significantly between wasted (2842 ±
363 kcal/day) and non‐wasted subjects (2532 ± 198 kcal/day, P = 0.71).
Two participants were taking no antiretroviral therapy, nine were taking monotherapy or dual
therapy (generally zidovudine (AZT) and lamivudine), and 14 were taking highly active
antiretroviral therapy, defined as taking two protease inhibitors or three or more drugs, in which at
least one was a protease inhibitor or a non‐nucleoside reverse transcriptase inhibitor. Subjects
were asked not to change their medication regimen during the study unless it was medically
necessary. No medication changes occurred during the first 8 week phase, but two patients began
protease inhibitors during the second 8 week phase. The median serum HIV RNA level was 8918
copies/ml (range undetectable to 45 899 copies/ml), and did not change significantly over the 16
weeks of follow‐up (Table 1). Mean CD4 count was 328 cells/ml (range 38–681 cells/ml, and did
not change significantly during the study (Table 1).
Of the 25 individuals who enrolled in the study, 24 (96%) completed the first 8 week phase, and 21
(84%) completed the second 8 week phase. Adherence with the exercise regimen was excellent,
with all 24 participants who completed phase 1 having a 90% or better attendance rate. One subject
dropped out in week 6 of the first phase because of scheduling problems. Three other men were
lost to follow‐up during the second phase: one left town because of an outstanding warrant for his
arrest, and two homeless men who could not be located within one month of their scheduled week
16 visit were excluded. The response to exercise in the dropouts was not significantly different
from those who continued the study in terms of strength change or change in body composition.

Effect of progressive resistance training on strength and body composition
After 8 weeks of PRT, the mean 1‐RM increased by 31 ± 18% for the chest press, 40 ± 23.6% for the
leg press, 50 ± 27% for the upper back, and 38 ± 31% for the quadriceps extension (all P < 0.0001
versus baseline; see Fig. 1). The increase in strength in men was larger than that in women for all
four machines (P < 0.05), but when the change in strength was expressed as a percentage of
baseline strength between the two sexes, this difference was not significant for any exercise (P >
0.26). Men and women thus responded to resistance training similarly in terms of strength change.
After 8 weeks of training, there was an increase in LBM of 1.75 ± 1.94 kg (mean ± SD, P < 0.0002
versus baseline) in the entire study group, with a concomitant decline in fat of 0.92 ± 2.22 kg (P <
0.05 versus baseline; see Fig. 2). Bone mineral content did not change significantly (–9.8 ± 128 g, P
< 0.7), nor did weight (+0.82 ± 2.45 kg, P < 0.12). There were no significant differences in these
changes between men and women, between patients receiving highly active antiretroviral therapy
and those not, between those ingesting more than 30 kcal/kg energy per day (n = 15) and those not,
or between those ingesting more than 1 g/kg protein per day (n = 14) and those not. Furthermore,
there was no correlation between the amount of lean gained and starting viral load, dietary energy
intake, or dietary protein intake.

Change in strength and body composition after 8 weeks of selfselected
activity
At the end of the PRT phase, subjects were asked to return to their usual activity pattern. The goal
of this phase was to examine the change in strength and body composition during a period of time
without investigator‐initiated intervention, in order to test the hypothesis that gains in strength
and body composition obtained during the first phase of the study would persist for an additional 8
weeks without further intervention. No dietary advice was given during the second phase of the
study beyond what all participants received as part of their participation in the larger cohort study
(eat a balanced diet, including adequate calories for weight maintenance and approximately 1.2
g/kg protein). Therefore, during this phase subjects were not trained at our center, nor were they
in contact with their trainers or dietitians from the first phase. At the end of 8 weeks of this phase,
21 of the 25 subjects returned to the GCRC for a repeat evaluation of their strength and body
composition (see Methods). As shown in Fig. 1, the improved strength seen after 8 weeks of PRT
was still present at week 16, after 8 weeks of self‐selected activity, for the leg press (P < 0.0001
versus baseline), chest press (P < 0.0003 versus baseline), upper back (P < 0.0001 versus baseline),
and quadriceps (P < 0.0005 versus baseline). Compared with week 8, only the upper back exercise
showed a significant decline in strength at week 16 (of 12.0 kg, P < 0.0002), whereas the 1‐RMs for
the other three exercises were not significantly reduced between weeks 8 and 16.
At week 16, the mean increase in lean mass in those who completed the entire study was 1.40 ± 1.8
kg (P < 0.003). The change in fat mass was, however, no longer significant (1.05 ± 3.3 kg, P < 0.18,
Fig. 2). Weight remained unchanged (–0.06 ± 4.1 kg, P = 0.95), as did bone mineral content (–16 ±
114, P =0.5). There was no difference in the gains at week 16 between the men and the women,
between black and white subjects, or between the two patients whose medication regimen changed
and the rest of the group.

Effect of continued individual training during phase 2
Nine of the subjects continued to lift weights at least once per week (mean 0.9 ± 0.4 sessions per
week) on their own at a nearby gym or health club, whereas the other 12 subjects performed no
further resistance training. Those who continued to train had a higher mean energy intake (2956 ±
709 versus 2237 ± 577 kcal/day, P < 0.03) and protein intake (117 ± 40 versus 81 ± 22.4 g/day, P <
0.04) at week 16 than those who stopped training, although their intakes had not differed at week
8. Because weights did not change during the second phase despite increased dietary intake, it is
reasonable to conclude that the physical activity level of the subjects who continued to train was
therefore higher than those who stopped training, so that both groups remained in energy balance.
There were no significant differences between these two subgroups in terms of their mean viral
load, CD4 counts, or medication use (data not shown). Compared with subjects who did not train,
those who did tended to have greater strength at week 16 in the leg press (P < 0.06) and chest press
(P < 0.07), but not on the leg extension or upper back exercises (P < 0.4 for both). Nonetheless,
among those who continued to train to some extent, lean mass increased by a mean of 1.1 ± 1.6 kg
over this 8 week period (P < 0.05 versus baseline), whereas those who did no further training
showed no change in lean mass (+0.23 ± 1.4 kg, P = NS versus baseline). The difference between the

two groups was not, however, significant (P < 0.2). The group who continued to exercise showed a
decline in fat mass of –0.15 ± 1.8 versus –0.15 ± 1.7 kg in the non‐exercising group (P = 0.95).

Effect of progressive resistance training in wasted subjects
Patients who met the criteria for AIDS wasting had a somewhat different response to PRT than that
seen in the weight‐stable patients (Fig. 3). All six subjects with wasting completed the entire
protocol. There was a tendency for lean mass in the wasted patients to increase more after 8 weeks
of PRT compared with the rest of the group (2.8 versus 1.4 kg, P < 0.08), and this trend persisted at
week 16 (2.4 versus 1.1 kg, P < 0.09). When the results of the non‐wasted subjects were analysed
excluding the wasted patients, the increase in lean mass remained significant (1.4 kg, P < 0.003).
Fat mass increased in the wasted patients at week 8, whereas it fell in the rest of the subjects (+
0.95 versus –1.5 kg, P < 0.002). This effect persisted at week 16 (+ 1.6 versus –1.9 kg, P < 0.01). As a
result, weight gain in the wasted patients was significantly greater than in the rest of the group at
both week 8 (+ 3.8 versus –0.2 kg, P < 0.002) and week 16 (+4.0 versus in –1.6 kg, P < 0.0002). In
addition, dietary energy (41.2 versus 32.6 kcal/kg, P < 0.12) and protein intake (1.65 versus 1.20
g/kg, P < 0.11) tended to be higher in the wasted patients than in the non‐wasted patients, perhaps
indicating a greater level of appetite stimulation by PRT in the wasted group.

Discussion
The results of this study suggest that a short period of intensive PRT is efficacious in increasing
strength and LBM, and reducing fat mass, in adults with HIV infection. The intensity of the
intervention was maintained by repeating 1‐RM measurements every 2 weeks, and by increasing
the resistance whenever subjects’ self‐reported relative perceived exertion dropped below 16 out
of 20 points on a Borg scale [22].
In addition, these data indicate for the first time that the gain in strength and lean mass in HIV‐
infected individuals is maintained during a short‐term follow‐up without further directed PRT. This
gain was maintained even in subjects who ceased training after the 8 week intervention period,
although not surprisingly it appeared that those subjects who elected to continue some form of PRT
on their own had continued increases in lean mass, whereas those who stopped training
maintained, but did not increase, their LBM. Continued training during the second phase of the
study was associated with higher caloric and protein intake, suggesting that the further increase in
LBM seen in this subgroup may have been caused by the effect of PRT on dietary intake, an effect
previously demonstrated in frail elderly nursing home patients [18]. The mixed results seen in
terms of strength change during the second 8 weeks of the study suggest that subjects reduced the
intensity, quantity, or type of workouts in the absence of a trainer, so that they maintained their
strength to a greater extent than the individuals who ceased training, but they did not continue to
gain strength at the same rate seen during the first 8 weeks of the study.
The magnitude of the increase in LBM seen in this study was similar to the 3 kg increase in lean
mass and 1.7 kg decrease in fat mass shown by Schambelan et al. [12] with 12 weeks of
recombinant human growth hormone treatment in patients with AIDS wasting, especially if their
results are compared with those seen in the subgroup of wasted patients in the current study. The

current results are also similar to those seen by Engelson et al. [14] with 12 weeks of testosterone
cypionate, which caused a 1.2 kg increase in lean mass and a 0.2 kg decrease in fat, estimated by
bioelectrical impedance. Gold et al. [13] examined LBM after 16 weeks of nandrolone decanoate in
an open‐label study in 24 patients with HIV infection, of whom 17 completed the study. They found
an increase of 3 kg in lean mass without a change in fat mass by anthropometry, but no significant
change in either compartment by bioelectrical impedance. In contrast, 12 weeks of megestrol
acetate increased lean mass by 1.1 kg, and fat mass by approximately 6 kg [11].
Only two previous published studies [23,24] of strength training have been reported in HIV‐
infected men. Rigsby et al. [24] examined the effect of combined aerobic and resistance training on
strength and aerobic fitness in 37 seropositive men. They found an increase in strength but did not
report changes in body composition. The only study to report body composition changes [23] used
a moderately intensive protocol, early in the HIV epidemic in 24 men who had recently recovered
from Pneumocystis carinii infection. They were all taking AZT, and were randomly assigned to
training or control (usual activity) intervention for 6 weeks. The subjects in the intervention group
were trained three times a week using a hydraulic isokinetic resistance training machine to train
the knee, shoulders, and chest in extension and flexion. There were significant improvements of
approximately 20% in power and torque production in the knee and shoulder with training,
compared with moderate deteriorations of approximately 10% in the control group. In addition,
there was a mean weight loss of 1.9 kg in the control group compared with a gain of 1.7 kg in the
training group (P < 0.0001), and a significant improvement in combined mid‐arm and mid‐thigh
circumference in the training group compared with a decline in the control group (P < 0.003). These
data, although encouraging, are difficult to interpret in the modern era of highly active anti‐
retroviral therapy, for several reasons. First, the study is limited to men, so its relevance to women
is unclear. Second, these men were recovering from
P. carinii pneumonia (PCP) at a time (1987–1988) when this condition, although treatable, was
often associated with poor long‐term survival, and the control subjects lost weight and strength
during the study. Third, the body composition response to the training program was measured
anthropometrically, which may have limited its precision. Finally, there was no follow‐up after the
exercise intervention to examine the durability of the effect.
In contrast, the patients in the current study were clinically stable, and were not suffering from
opportunistic infections or other acute illnesses. AIDS wasting was not required for entry into this
study, since it is likely that improved strength and lean mass will be beneficial to all patients with
HIV, and may be more useful as a preventive than a therapeutic measure, to increase body protein
stores before acute illness occurs. Unlike other studies [24,25] of aerobic or aerobic plus moderate
resistance training in HIV‐infected adults, which reported dropout rates of 20 and 76%, we had a
very low dropout rate during the exercise study (one out of 25 subjects, or 4%), and only a slightly
higher rate during the follow‐up period (three out of 24 subjects, or 12.5%), despite a high
proportion of homeless participants. There were no injuries associated with the PRT protocol, and
the subjects were generally adherent to the 3 day per week schedule. A surprising result of this
study is that PRT caused both lean and fat gain in wasted subjects, whereas the patients without
clinical wasting experienced a gain in lean and a loss of fat, as has been reported in studies of non‐

HIV‐infected adults [26]. We chose to study untrained patients without requiring wasting as a
criterion of entry to the study, because increasing protein stores and strength by increasing muscle
should be of benefit to patients with HIV, regardless of whether or not they have wasting. The
results seen in this study are advantageous to both groups, as the wasted patients benefit from
increases in both fat and lean mass, whereas the heavier subjects benefit from reducing their fat
mass as well as from increasing their lean mass. To our knowledge this is the first demonstration of
such an effect by any anabolic intervention.
There are several limitations of this study that should be considered. First, there was no control
group, largely because when the study was first designed in 1993, we could not recruit subjects for
a randomized study. We are now recruiting patients with evidence of unintentional weight loss or a
low BMI for such a controlled trial. In a previous study [19] of healthy HIV‐negative individuals,
using the same training methods, equipment, assessment techniques, and DXA methods, we found
that 24 sessions of sham exercise over 12 weeks, consisting of stretching and swimming for 30 min,
did not alter strength (mean change in 1‐RM, 9 ± 8%) or LBM (–0.8 ± 1.0 kg). In addition, there is a
wealth of information indicating that spontaneous increases in LBM, our primary outcome, do not
occur even in healthy weight‐stable adults over time [27], and are not expected to occur in HIV‐
infected adults. Rather, the opposite is true: a decline in muscle mass occurs with normal ageing
[27], and is accelerated in HIV infection [1,5]. A before–after study design, which implicitly assumes
a comparison of the results seen to a null hypothesis of no change, thus seems reasonable to test the
efficacy of PRT. Furthermore, the post‐exercise ad libitum activity phase of the study offered an
opportunity to assess the durability of the increase in LBM achieved during the first 8 weeks: a
further increase in lean mass was seen only in the subjects who continued to train, whereas no
further increase was seen in the subjects who stopped training.
Another limitation is the short duration of the intervention period. When this study was first
submitted for funding in 1993, there was concern about the duration of intervention that could be
done without a change in medications that might alter weight and thus lean and fat mass. Although
medication stability for a longer duration is now easier to achieve, eliminating this potentially
significant confounder was sufficiently important to warrant a short study. On the other hand, this
should not be taken to suggest that a longer period of PRT would not have a larger effect on lean
mass and strength, as shown by the subgroup of patients who chose to continue to train on their
own during the second phase of the study. In previous studies [28], continued improvement in
strength and body composition without a plateau effect was seen for up to a year in elderly women.
The 8 week PRT phase of this study may, however, be considered a model for an intensive
rehabilitative approach to repleting lean mass and strength in HIV‐infected individuals, which could
be followed in clinical practice by a maintenance phase of less intensive exercise. The
demonstration of the efficacy of PRT in the current study, if replicated in larger trials, may be
helpful in convincing third party payers to reimburse for an 8 week intensive PRT treatment in the
future.
Data from this study are consistent with those seen in other strength training studies [26], which
suggest that in order to cause muscle hypertrophy and increase LBM, weight‐lifting must be
intensive, progressive, and must be performed regularly. Most untrained persons will not

spontaneously exercise at such an intensive level, nor will they increase the weight without
prompting. In this, the role of the trainer is crucial in providing encouragement, promoting good
form, and assisting with both the intensiveness and progressiveness of the regimen, at least
initially. Studies or clinical applications of PRT, which do not include safeguards to ensure that a
high level of resistance training is maintained, are unlikely to be successful. The willingness of third
party payers to reimburse for training will be a major determinant of the applicability of PRT to the
HIV‐infected population.
In conclusion, this study indicates that PRT has the potential to increase strength and lean mass in
patients with HIV infection. Perhaps of equal importance in the age of highly active antiretroviral
therapy and the increasing prevalence of abdominal obesity and fat redistribution [29,30], PRT can
also reduce fat mass. Moreover, these improvements were maintained over a short‐term follow‐up,
and a substantial proportion of patients who had been taught to perform PRT continued to do so on
their own after the training phase of the study ended. These data indicate that PRT offers an
alternative to pharmacological anabolic treatment to build LBM in HIV infection. Direct
comparisons of PRT with other anabolic treatments are now in progress, and consideration should
be given to how to incorporate PRT into clinical care in HIV infection.
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Tables & Figures
Table 1: Demographic and Clinical Characteristics of the Study Population
Parameter
Male:female
Age
Ethnicity – white: African–American
HIV risk factor
Intravenous drug use
Homosexual
Transfusion
Antiretroviral therapy
None
Monotherapy/dual therapy
HAART
CD4 count/ml
Circulating HIV RNA, copies/ml
Hemoglobin, g/dl
Dietary intake
Energy, kcal/day
Protein, g/day
Body composition
Weight, kg
Lean body mass, kg
Fat mass, kg
Bone mineral content, kg

Baseline
20:5
38.8 (7.8)
14:11

Week 8
19:5
–
14:10

Week 16
16:5
–
12:9

9
15
1

8
15
1

4
15
1

2
9
14
328 (151)
8919 (18 408)
14.0 (1.3)

2
8
14
303 (189)
9272 (22 386)
14.0 (1.2)

2
7
12
357 (172)
8752 (20 998)
13.8 (1.3)

2590 (723)
97.3 (34.7)

2604 (778)
102.7 (38.6)

2456 (682)
99.6 (33.9)

76.0 (14.1)
53.1 (7.7)
20.3 (11.7)
2.6 (0.4)

76.9 (13.9)
54.9 (8.9)
19.4 (11.0)
2.6 (0.4)

77.8 (14.1)
55.1 (8.8)
20.3 (12.7)
2.6 (0.4)

Data are mean (SD) unless otherwise indicated. HAART, Highly active antiretroviral therapy.
Compartment weights may not add up to total weight due to rounding.

Figure 1

One‐repetition maximum strength (lb) at baseline, after 8 weeks of PRT, and after an additional 8
weeks of ad libitum activity for each of the four exercise machines used in the study. Note that the
leg press results are shown divided by 10 in order to fit on the same scale as the other machines. All
changes are significant (P <0.0001) versus baseline at both 8 and 16 weeks. See text for statistical
details.

Figure 2

Change from baseline in LBM, fat mass and bone mass at the end of the 8 week PRT phase of the
study and at the end of the 16 week study period. *P<0.05; **P <0.003; *** P <0.0002, all versus
baseline.

Figure 3

Change from baseline in LBM and fat mass at the end of 8 weeks of PRT and at the end of the 16
week study period, in subjects with or without AIDS wasting. †P < 0.09; **P <0.002

